Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders

Taregh Bamedi; Ghazaleh Dadashizadeh; Afsaneh Sarabandi; Shadi Tabibian; Mahmood Shams; Akbar Dorgalaleh

doi:10.22037/jcma.v2i1.14481

Journal of Cellular & Molecular Anesthesia

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement New Publisher Announcement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v2i1.14481

Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders

Author(s):

Taregh Bamedi^1,*,

Ghazaleh Dadashizadeh²,

Afsaneh Sarabandi³,

Shadi Tabibian⁴,

Mahmood Shams⁵,

Akbar Dorgalaleh⁴

1Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran

2Department of Hematology and Blood Transfusion, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3Department of Nursing, Faculty of Medical Sciences, Islamic Azad University, Zahedan Branch, Zahedan, Iran

4Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

5Department of Laboratory Sciences, Paramedical Faculty, Babol University of Medical Sciences, Babol

Journal of Cellular & Molecular Anesthesia:Vol. 2, issue 1; e149529

Published online:Jan 01, 2017

Article type:Review

How to Cite:Taregh BamediGhazaleh DadashizadehAfsaneh SarabandiShadi TabibianMahmood ShamsAkbar Dorgalalehet al.Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders.J Cell Mol Anesth.2(1):e149529.https://doi.org/10.22037/jcma.v2i1.14481.

Abstract

Inhibitor development is a lifelong challenge for patients with bleeding disorders who received replacement therapy. Most commonly, inhibitor formation was observed in hemophilia A patients but patients with rare bleeding disorders (RBD) especially patients with deficiency of factor XIII (FXIII) and factor V (FV) can develop an inhibitor against exogenous factors. Several factors considered as risk factors for inhibitor formations in these patients. Genetic risk factors are the main accused that can cause inhibitor formation in hemophilia patients but are less important in RBDs.For this review study, we searched MEDLINE and Web of Science databases for English sources and the following key words: hemophilia, inhibitor, rare bleeding disorder, rare inherited disorder, acquired hemophilia, acquired rare bleeding disorders, treatment complication, genetic in hemophilia, polymorphism in rare bleeding disorder, mutation in hemophilia and other required keywords.Hemophilia A (HA) patients who had large deletion, nonsense mutation or intron 22 inversion are more susceptible for inhibitor development. Gene polymorphisms in immune system are also considered as other risk factors in HA patients.Keywords: ?Hemophilia, rare bleeding disorder, inhibitor

Keywords

Hemophilia

rare bleeding disorder

inhibitor

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Taregh Bamedi:[PubMed][Scholar]
Ghazaleh Dadashizadeh:[PubMed][Scholar]
Afsaneh Sarabandi:[PubMed][Scholar]
Shadi Tabibian:[PubMed][Scholar]
Mahmood Shams:[PubMed][Scholar]
Akbar Dorgalaleh:[PubMed][Scholar]